Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities researchers at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued on Thursday. Jefferies Group analyst M. Andrews anticipates that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter. Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.18) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.32) EPS, FY2019 earnings at $1.38 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.71 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The company had revenue of $42.06 million for the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative return on equity of 7.88% and a negative net margin of 6.54%. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 earnings per share.

ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. Expected to Earn Q3 2017 Earnings of ($0.13) Per Share (NASDAQ:VNDA)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/vanda-pharmaceuticals-inc-expected-to-earn-q3-2017-earnings-of-0-13-per-share-nasdaqvnda.html.

VNDA has been the topic of several other reports. Oppenheimer Holdings, Inc. started coverage on Vanda Pharmaceuticals in a research report on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 price target on the stock. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 18th. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. Finally, HC Wainwright set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Vanda Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $21.22.

Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at 16.00 on Monday. Vanda Pharmaceuticals has a 12 month low of $11.58 and a 12 month high of $18.00. The stock’s 50 day moving average price is $15.89 and its 200-day moving average price is $14.60. The firm’s market capitalization is $715.49 million.

Hedge funds have recently modified their holdings of the company. Cheyne Capital Management UK LLP increased its stake in shares of Vanda Pharmaceuticals by 42.3% in the first quarter. Cheyne Capital Management UK LLP now owns 74,000 shares of the biopharmaceutical company’s stock valued at $1,034,000 after buying an additional 22,000 shares during the last quarter. Weiss Multi Strategy Advisers LLC increased its stake in shares of Vanda Pharmaceuticals by 20.0% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $840,000 after buying an additional 10,000 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock valued at $8,600,000 after buying an additional 4,700 shares during the last quarter. American International Group Inc. increased its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after buying an additional 1,491 shares during the last quarter. Finally, FMR LLC increased its stake in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock valued at $22,416,000 after buying an additional 604,900 shares during the last quarter. 91.35% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.